News & Statements
T1International and #insulin4all Advocates Score Major Win
1 Mar 2023, 11:43 a.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more
T1International Patients Speak out about US Patent Process
20 Feb 2023, 4:47 p.m. in #insulin4all USA, News & Statements by T1International
Patents are intended to provide an exclusive right for a novel invention. By granting a protected property right to an inventor, patents are intended to spur innovation because the patent holder can make significant money for a limited time in exchange for publishing and disclosing the invention. However, the patent system has been exploited by Big Pharma to keep charging high prices on old insulins, or only changing their products in small ways. Read more
Diabetes burnout: a common but neglected impact of diabetes
9 Jan 2023, 6:46 p.m. in #insulin4all USA, Global Stories, News & Statements by Konstantina Taki, Ian Devaney
Research conducted by T1International finds that people living with diabetes are experiencing diabetes burnout at a very high rate, with a significant impact on their health and wellbeing. Read more
T1I’s Top 14 of 2022: A Year in Review
19 Dec 2022, 9:34 a.m. in #insulin4all USA, News & Statements by T1International
With many successes and key moments to reflect on, it is nearly impossible to recap all in a single post. Instead, you can hear favorite moments directly from the 14 members of the T1International team! Read more
Health is Wealth: Direct Action Recap
18 Nov 2022, 8:16 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Voices from around the world were part of the T1International Rally and March outside Eli Lilly on October 24th, where #insulin4all activists demanded Eli Lilly immediately lower the list price of insulin and defended the lives of those who are rationing insulin just to survive. Read more
New Rationing Data Reinforces T1International’s Call for Insulin Price Cap
17 Oct 2022, 10:11 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
A recent study of 2021 National Health Interview Survey data demonstrates what #insulin4all advocates have been saying for years: too many people are dangerously rationing insulin due to cost. While insulin costs around $6 to manufacture, three companies dominate more than 90% of the insulin market and charge around $300 for a single vial of insulin. Read more
Taking Action for Health is Wealth
13 Oct 2022, noon in #insulin4all USA, Global Stories, News & Statements by T1International
T1International’s virtual #insulin4all Summit, Health is Wealth, was held on September 24th. Thank you everyone for your participation and read our recap here! Read more
The Long Road to US Federal Insulin Law and What More Needs to be Done
16 Sep 2022, noon in #insulin4all USA, News & Statements by T1International
The journey to move towards a federal insulin price cap has been long and difficult, including challenging incremental steps. The fight for a true insulin price cap in the US continues. Read more
5 Ways To Combat Pharma Talking Points with Just the Facts
12 Aug 2022, 6 a.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Misinformation about diabetes and insulin is all too regularly spread in both the media and on social platforms. In this post, we outline 5 of the most common talking points used to explain away price gouging and how we can use the facts to overcome this narrative. Read more
Calling for Empowered Implementation of Global Diabetes Coverage Targets
11 Jul 2022, 9:59 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
At the 75th World Health Assembly (WHA) of the World Health Organization (WHO), member states adopted the first ever ‘Global Diabetes Coverage Targets,’ meant to steer the course of diabetes diagnosis and treatment for the next 8 years. Read more